Combinations of HER2 antibodies

By combining specific anti-HER2 antibodies with trastuzumab or pertuzumab, the drug resistance problem has been solved for HER2-positive cancers, achieving stronger tumor growth inhibition and apoptosis induction, thus enhancing the therapeutic effect.

CN113924116BActive Publication Date: 2025-11-25MAB DISCOVERY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202080032056.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-02
Filing Date
2020-04-29
Publication Date
2025-11-25
Estimated Expiration
2040-04-29

AI Technical Summary

Technical Problem

Existing HER2-targeted therapies have primary and secondary resistance issues in HER2-positive cancers, resulting in some patients not responding to trastuzumab and pertuzumab treatments. There is a need to develop new antibodies or treatment methods to improve efficacy.

Method used

Using specific anti-HER2 antibodies targeting the epitopes between amino acids 342 and 652 of human HER2, combined with trastuzumab or pertuzumab, a combination therapy is formed to enhance the treatment effect on HER2-positive cancers.

Benefits of technology

This combination therapy demonstrated significant tumor growth inhibition and apoptosis induction in in vitro and in vivo experiments, superior to trastuzumab or pertuzumab alone, especially exhibiting strong apoptosis induction and ADCC effects in drug-resistant breast cancer cell lines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003325761150000041
    Figure BDA0003325761150000041
  • Figure BDA0003325761150000051
    Figure BDA0003325761150000051
  • Figure BDA0003325761150000071
    Figure BDA0003325761150000071
Patent Text Reader

Abstract

The present invention relates to the use of a HER2 antibody directed against an epitope between amino acids 342-652 of human HER2 in combination with a second HER2 inhibitor for the treatment of a HER2-related disorder. More specifically, the present invention relates to methods and uses of MAB270 or an antibody having the same CDRs as MAB270 in combination with trastuzumab or pertuzumab in a HER2-positive cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Antibody specifically binding to HER2

    CN105164160A

  • HER-2 binding antibodies

    CN109415443A